Have a feature idea you'd love to see implemented?
Let us know!
RGEN Repligen Corp
Price (delayed)
$141.76
Market cap
$7.94B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.14
Enterprise value
$7.83B
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in
Highlights
RGEN's quick ratio has surged by 58% since the previous quarter
RGEN's gross profit is up by 15% QoQ and by 6% YoY
The debt has soared by 60% YoY but it has contracted by 9% from the previous quarter
The revenue has contracted by 2.9% YoY but it has grown by 2.2% from the previous quarter
The company's net income has shrunk by 185% QoQ and by 108% YoY
RGEN's EPS has dropped by 182% since the previous quarter and by 108% year-on-year
Key stats
What are the main financial stats of RGEN
Market
Valuations
Earnings
Shares outstanding
56.03M
Market cap
$7.94B
Enterprise value
$7.83B
Price to book (P/B)
3.94
Price to sales (P/S)
12.53
EV/EBIT
261.18
EV/EBITDA
66
EV/Sales
12.36
Revenue
$633.51M
EBIT
$29.98M
EBITDA
$118.65M
Free cash flow
$132.52M
Per share
Balance sheet
Liquidity
EPS
-$0.14
Free cash flow per share
$2.37
Book value per share
$36.01
Revenue per share
$11.31
TBVPS
$26.11
Total assets
$2.83B
Total liabilities
$813.96M
Debt
$672.47M
Equity
$2.02B
Working capital
$1.02B
Debt to equity
0.33
Current ratio
10.44
Quick ratio
8.43
Net debt/EBITDA
-0.94
Margins
Efficiency
Dividend
EBITDA margin
18.7%
Gross margin
49.6%
Net margin
-1.3%
Operating margin
1.8%
Return on assets
-0.3%
Return on equity
-0.4%
Return on invested capital
2.4%
Return on capital employed
1.1%
Return on sales
4.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGEN stock price
How has the Repligen stock price performed over time
Intraday
2.06%
1 week
-0.47%
1 month
-4.99%
1 year
-9.71%
YTD
-21.16%
QTD
-4.74%
Financial performance
How have Repligen's revenue and profit performed over time
Revenue
$633.51M
Gross profit
$314.29M
Operating income
$11.26M
Net income
-$8.1M
Gross margin
49.6%
Net margin
-1.3%
The net margin has plunged by 187% from the previous quarter and by 108% YoY
The company's net income has shrunk by 185% QoQ and by 108% YoY
The operating income has plunged by 87% YoY and by 53% from the previous quarter
The operating margin has plunged by 86% YoY and by 53% from the previous quarter
Growth
What is Repligen's growth rate over time
Valuation
What is Repligen stock price valuation
P/E
N/A
P/B
3.94
P/S
12.53
EV/EBIT
261.18
EV/EBITDA
66
EV/Sales
12.36
RGEN's EPS has dropped by 182% since the previous quarter and by 108% year-on-year
The P/B is 30% less than the 5-year quarterly average of 5.6 and 12% less than the last 4 quarters average of 4.5
Repligen's equity has increased by 2.2% YoY
RGEN's P/S is 28% below its 5-year quarterly average of 17.3 and 12% below its last 4 quarters average of 14.2
The revenue has contracted by 2.9% YoY but it has grown by 2.2% from the previous quarter
Efficiency
How efficient is Repligen business performance
RGEN's ROA has dropped by 200% since the previous quarter and by 108% year-on-year
The return on equity has dropped by 180% since the previous quarter and by 108% year-on-year
The ROIC has plunged by 83% YoY and by 29% from the previous quarter
RGEN's return on sales has dropped by 72% year-on-year and by 23% since the previous quarter
Dividends
What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGEN.
Financial health
How did Repligen financials performed over time
Repligen's current ratio has surged by 58% QoQ
RGEN's quick ratio has surged by 58% since the previous quarter
The debt is 67% less than the equity
The debt has soared by 60% YoY but it has contracted by 9% from the previous quarter
Repligen's debt to equity has soared by 57% YoY but it has decreased by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.